VaxThera
News
2025
VaxThera and Seguros SURA Launch Colombia’s Largest Regional Program to Prevent HPV Associated Cancer
Medellín, September 2025. In Colombia, cervical cancer is the leading cause of cancer-related death among women aged 20 to 35, largely driven by Human Papillomavirus...
2026
VaxThera, GC Biopharma and RIGHT Foundation Advance Influenza Vaccine Technology Transfer in Colombia
The project brings together international funding, proven vaccine expertise and local capabilities to strengthen vaccine manufacturing in Colombia and Latin America. VaxThera S.A.S., GC Biopharma...
2026
VaxThera and Serum Institute of India Announce a Strategic Collaboration to Strengthen Vaccine Development and Health Security in Colombia
Medellín, Colombia VaxThera SAS (www.vaxthera.com), a Colombian-based biotechnology company, announced a strategic collaboration with Serum Institute of India (SII), a Cyrus Poonawalla group company and...
2026
EIB, European Commission and VaxThera boost Latin America’s vaccine capacity by up to 250 million doses a year
The European Investment Bank (EIB), in partnership with the European Commission, is providing a €15 million venture loan to VaxThera, a Colombian biotechnology company developing,...
2026
VaxThera and Codagenix Partner to Advance a Next Generation Yellow Fever Vaccine
Medellín, Colombia, and Farmingdale, Nueva York, September 16th 2026. VaxThera S.A.S., a Colombian biotechnology company developing and manufacturing vaccines and advanced biological products (“VaxThera”), and...
2026
VaxThera and Hetero announce strategic alliance to expand access to high-cost biologic therapies
Collaboration begins with three monoclonal antibodies and establishes a pathway toward technology transfer and local production in Colombia for Latin America MEDELLÍN, Colombia. VaxThera S.A.S.,...
